GSK PLC on Thursday said its monoclonal antibody Nucala, also known as mepolizumab, has been accepted for review in China. The London-based pharmaceutical company said the China Medical Products ...

GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

Pembrolizumab is a checkpoint inhibitor that binds to the protein PD-1 on T cells to help them recognize and attack invaders.

GlaxoSmithKline Pharmaceuticals Limited ... a second-generation anti-histamine and research product of UCB Pharma (Belgium) was launched under a co-marketing agreement. In the same year Glaxo ...

Drug company executives on Tuesday touted their industry’s work to keep and make Americans healthy during a Washington event.

Embedding the patient voice into the DNA of a pharmaceutical company ... VP and country medical director, UK and Ireland at GSK, which has a dedicated Patients in Partnership team working to ...

For tech companies, the healthcare vertical is now the fastest growing business. The US, which spends about $5 trillion on ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Ovarian cancer continues to pose a significant challenge in the medical field, remaining one of the leading causes of death ...

The global Benign Prostatic Hyperplasia Surgical Treatment market, valued at US$11.92 billion in 2023, is forecasted to grow at a robust CAGR ...

Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...

While for some individuals it has increased trust in vaccination and the pharma industry ... during which Piyali Mukherjee, GSK’s head of global medical affairs, vaccines, outlined why adult ...